Compare GSK plc (GSK) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

LBTYK trades at $10.49, up 1.16% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported a significant net loss of -$7.14B in 2025 despite $4.88B revenue, though Q1 2026 showed improvement with a positive EPS beat. Analyst sentiment remains strongly bullish with 69% buy ratings, driven by the planned 2027 Ziggo Group spin-off as a key catalyst.

The stock presents a high-risk opportunity with potential upside from sum-of-the-parts valuation and spin-off catalysts, but faces substantial execution risks given persistent losses and competitive telecom pressures. Current valuation metrics (P/S 0.72, P/B 0.37) suggest deep discount to intrinsic value if restructuring succeeds.